Alexion

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ claims full control of Caelum's AL amyloidosis drug in $5...

AstraZeneca's newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal that could be worth up to $500 million.

News

After Ultomiris stumble, Alexion delivers a rare disease win...

A drug for Wilson disease developed by AstraZeneca's Alexion rare disease unit has cleared a phase 3 trial, setting up regulatory filings in the coming months.

News

AZ's Alexion plans hit a snag as Ultomiris flunks ALS trial

It has only been a month since AstraZeneca's $39 billion takeover of Alexion was completed, but the new combination has already had a setback.

News

Boost for AZ as Ultomiris gets CHMP nod for expanded label

Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion of the label of Ultomiris, one of the main assets behind the

News

Final hurdle falls as UK backs AZ's $39bn takeover of Alexio...

The UK's competition regulator has approved AstraZeneca's $39 billion acquisition of US-based drugmaker Alexion, without opting for a broader inquiry into the deal.

News

Another hurdle down as EU clears AstraZeneca's Alexion takeo...

The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across th

AZ claims full control of Caelum's AL amyloidosis drug in $5...

After Ultomiris stumble, Alexion delivers a rare disease win...

AZ's Alexion plans hit a snag as Ultomiris flunks ALS trial

Boost for AZ as Ultomiris gets CHMP nod for expanded label

Final hurdle falls as UK backs AZ's $39bn takeover of Alexio...

Another hurdle down as EU clears AstraZeneca's Alexion takeo...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Alexion

Editor's Picks